Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, cross-over trial

Diabetes, Obesity and Metabolism

Volumn 15, Issue 11, 2013, Pages 1040-1048

  Hermansen, K ^a   Baekdal T A ^b   During M ^b   Pietraszek, A ^a   Mortensen, L S ^a   Jorgensen H ^c   Flint, A ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b NOVO NORDISK A S   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

Author keywords

Antidiabetic drug; GLP 1 analogue; Lipid lowering therapy; Phase I II study; Randomized trial; Type II diabetes

Indexed keywords

APOLIPOPROTEIN B48; CARBON 13; FATTY ACID; LIRAGLUTIDE; OCTANOIC ACID; PARACETAMOL; PLACEBO; SULFONYLUREA; TRIACYLGLYCEROL;

ADULT; AGED; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BODY MASS; BREATH ANALYSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONNECTIVE TISSUE DISEASE; CONSTIPATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG TOLERABILITY; DYSESTHESIA; DYSPEPSIA; EAR DISEASE; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPOGLYCEMIA; INNER EAR DISEASE; LIPID DIET; MALE; MAXIMUM PLASMA CONCENTRATION; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL DISORDER; PNEUMONIA; POSTPRANDIAL STATE; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; STEADY STATE; STOMACH EMPTYING; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VERTIGO; VOMITING;

ANTIDIABETIC DRUG; GLP-1 ANALOGUE; LIPID-LOWERING THERAPY; PHASE I-II STUDY; RANDOMIZED TRIAL; TYPE II DIABETES;

AGED; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CROSS-OVER STUDIES; DENMARK; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; DOUBLE-BLIND METHOD; FEMALE; GASTRIC EMPTYING; GERMANY; GLUCAGON-LIKE PEPTIDE 1; HALF-LIFE; HUMANS; HYPERLIPIDEMIAS; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; LIPIDS; MALE; MIDDLE AGED; OBESITY; POSTPRANDIAL PERIOD; RISK FACTORS;

EID: 84885300888     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12133     Document Type: Article

References (44)

1. International Diabetes Federation. IDF Diabetes Atlas. 5th edn. Brussels: International Diabetes Federation, 2011.
2. Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003; 46: 733-749.
3. Turner RC, Millns H, Neil HA et al. Risk factorsfor coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998; 316: 823-828.
4. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007; 298: 299-308.
5. Karpe F. Postprandial lipoprotein metabolism and atherosclerosis. J Intern Med 1999; 246: 341-355.
6. Carstensen M, Thomsen C, Gotzsche O, Holst JJ, Schrezenmeir J, Hermansen K. Differential postprandial lipoprotein responses in type 2 diabetic men with and without clinical evidence of a former myocardial infarction. Rev Diabet Stud 2004; 1: 175-184.
7. Wallace JP, Johnson B, Padilla J, Mather K. Postprandial lipaemia, oxidative stress and endothelial function: a review. Int J Clin Pract 2010; 64: 389-403.
8. Hsieh J, Longuet C, Baker CL et al. The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia 2010; 53: 552-561.
9. Meier JJ, Gethmann A, Gotze O et al. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia 2006; 49: 452-458.
10. Tremblay AJ, Lamarche B, Deacon CF, Weisnagel SJ, Couture P. Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes. Diabetes Obes Metab 2011; 13: 366-373.
11. Matikainen N, Manttari S, Schweizer A et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 2006; 49: 2049-2057.
12. Schwartz EA, Koska J, Mullin MP, Syoufi I, Schwenke DC, Reaven PD. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus. Atherosclerosis 2010; 212: 217-222.
13. DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin 2008; 24: 2943-2952.
14. Bunck MC, Corner A, Eliasson B et al. One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress. Atherosclerosis 2010; 212: 223-229.
15. Blonde L, Russell-Jones D. The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies. Diabetes Obes Metab 2009; 11(Suppl. 3): 26-34.
16. Bandsma RH, Lewis GF. Newly appreciated therapeutic effect of GLP-1 receptor agonists: reduction in postprandial lipemia. Atherosclerosis 2010; 212: 40-41.
17. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
18. Willems M, Quartero AO, Numans ME. How useful is paracetamol absorption as a marker of gastric emptying? A systematic literature study. Dig Dis Sci 2001; 46: 2256-2262.
19. Zahn A, Langhans CD, Hoffner S et al. Measurement of gastric emptying by 13C-octanoic acid breath test versus scintigraphy in diabetics. Z Gastroenterol 2003; 41: 383-390.
20. Agerso H, Jensen LB, Elbrond B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002; 45: 195-202.
21. Kinoshita M, Kojima M, Matsushima T, Teramoto T. Determination of apolipoprotein B-48 in serum by a sandwich ELISA. Clin Chim Acta 2005; 351: 115-120.
22. Ghoos YF, Maes BD, Geypens BJ et al. Measurement of gastric emptying rate of solids by means of a carbon-labeled octanoic acid breath test. Gastroenterology 1993; 104: 1640-1647.
23. Mortensen LS, Hartvigsen ML, Brader LJ et al. Differential effects of protein quality on postprandial lipemia in response to a fat-rich meal in type 2 diabetes: comparison of whey, casein, gluten, and cod protein. Am J Clin Nutr 2009; 90: 41-48.
24. Matikainen N, Taskinen MR. The effectof vildagliptin therapy on atherogenic postprandial remnant particles and LDL particle size in subjects with type 2 diabetes. Diabet Med 2012; 30: 756-757.
25. Eleftheriadou I, Grigoropoulou P, Katsilambros N, Tentolouris N. The effects of medications used for the management of diabetes and obesity on postprandial lipid metabolism. Curr Diabetes Rev 2008; 4: 340-356.
26. Tentolouris N, Eleftheriadou I, Katsilambros N. The effects of medications used for the management of dyslipidemia on postprandial lipemia. Curr Med Chem 2009; 16: 203-217.
27. Thomsen C, Storm H, Holst JJ, Hermansen K. Differential effects of saturated and monounsaturated fats on postprandial lipemia and glucagon-like peptide 1 responses in patients with type 2 diabetes. Am J Clin Nutr 2003; 77: 605-611.
28. Lairon D, Defoort C. Effects of nutrients on postprandial lipemia. Curr Vasc Pharmacol 2011; 9: 309-312.
29. Claessens M, Calame W, Siemensma AD, van Baak MA, Saris WH. The effect of different protein hydrolysate/carbohydrate mixtures on postprandial glucagon and insulin responses in healthy subjects. Eur J Clin Nutr 2009; 63: 48-56.
30. Degn KB, Juhl CB, Sturis J et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004; 53: 1187-1194.
31. Flint A, Kapitza C, Hindsberger C, Zdravkovic M. The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients. Adv Ther 2011; 28: 213-226.
32. Hanefeld M. Pioglitazone and sulfonylureas: Effectively treating type 2 diabetes. Int J Clin Pract 2007; 61: 20-27.
33. Cunningham KM, Read NW. The effect of incorporating fat into different components of a meal on gastric emptying and postprandial blood glucose and insulin responses. Br J Nutr 1989; 61: 285-290.
34. Jelsing J, Vrang N, Hansen G, Ravn K, Tang-Christensen M, Knudsen LB. Liraglutide: short lived effect on gastric emptying - long lasting effects on body-weight. Diab Obesity Metabol 2012; 14: 531-538.
35. Nauck MA, Kemmeries G, Holst JJ, Meier JJ. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes 2011; 60: 1561-1565.
36. Kapitza C, Zdravkovic M, Hindsberger C, Flint A. The effect of the once-daily human glucagon-like peptide 1 analog liraglutide on the pharmacokinetics of acetaminophen. Adv Ther 2011; 28: 650-660.
37. Horowitz M, Flint A, Jones KL et al. Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. Diabetes Res Clin Pract 2012; 97: 258-266.
38. Nesto RW. LDL cholesterol lowering in type diabetes: What is the optimum approach? Clin Diabetes 2008; 26: 8-13.
39. Miller M. Raising an isolated low HDL-C level: Why, how, and when? Cleve Clin J Med 2003; 70: 553-560.
40. Neumiller JJ, Campbell RK. Liraglutide: a once-daily incretin mimetic for the treatment of type 2 diabetes mellitus. Ann Pharmacother 2009; 43: 1433-1444.
41. Garber A, Henry R, Ratner R et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373: 473-481.
42. Lando HM, Alattar M, Dua AP. Elevatedamylase and lipase in patients using GLP-1 receptor agonists or DPP-4 inhibitors in the outpatient setting. Endocr Pract 2012; 18: 472-477.
43. Marso SP, Lindsey JB, Stolker JM et al. Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2: 3 liraglutide clinical development studies. Diab Vasc Dis Res 2011; 8: 237-240.
44. Ooi TC, Nordestgaard BG. Methods to study postprandial lipemia. Curr Vasc Pharmacol 2011; 9: 302-308.